ZA200308561B - Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors. - Google Patents

Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors.

Info

Publication number
ZA200308561B
ZA200308561B ZA200308561A ZA200308561A ZA200308561B ZA 200308561 B ZA200308561 B ZA 200308561B ZA 200308561 A ZA200308561 A ZA 200308561A ZA 200308561 A ZA200308561 A ZA 200308561A ZA 200308561 B ZA200308561 B ZA 200308561B
Authority
ZA
South Africa
Prior art keywords
self
transfer protein
cholesteryl ester
protein inhibitors
ester transfer
Prior art date
Application number
ZA200308561A
Other languages
English (en)
Inventor
Gumkowski Michael Jon
Murdande Sharad Balasaheb
Perlman Michael Ellis
Franco LOMBARDO
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ZA200308561B publication Critical patent/ZA200308561B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/47064-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
  • Emulsifying, Dispersing, Foam-Producing Or Wetting Agents (AREA)
  • Colloid Chemistry (AREA)
  • Quinoline Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Steroid Compounds (AREA)
ZA200308561A 2001-06-21 2003-11-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors. ZA200308561B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30002801P 2001-06-21 2001-06-21

Publications (1)

Publication Number Publication Date
ZA200308561B true ZA200308561B (en) 2004-11-17

Family

ID=23157363

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200308561A ZA200308561B (en) 2001-06-21 2003-11-03 Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors.

Country Status (33)

Country Link
US (2) US6962931B2 (xx)
EP (1) EP1453544A2 (xx)
JP (1) JP2005500314A (xx)
KR (1) KR20040015746A (xx)
CN (1) CN1635911A (xx)
AP (1) AP2002002559A0 (xx)
AR (1) AR034599A1 (xx)
BG (1) BG108486A (xx)
BR (1) BR0210505A (xx)
CA (1) CA2455288A1 (xx)
CR (1) CR7163A (xx)
CZ (1) CZ20033341A3 (xx)
EA (1) EA200301139A1 (xx)
EC (1) ECSP034875A (xx)
EE (1) EE200400024A (xx)
GT (1) GT200200124A (xx)
HN (1) HN2002000153A (xx)
HU (1) HUP0400263A2 (xx)
IL (1) IL158765A0 (xx)
IS (1) IS7014A (xx)
MA (1) MA27034A1 (xx)
MX (1) MXPA04000014A (xx)
NO (1) NO20035632L (xx)
OA (1) OA12619A (xx)
PA (1) PA8548601A1 (xx)
PE (1) PE20030128A1 (xx)
PL (1) PL368850A1 (xx)
SK (1) SK15172003A3 (xx)
SV (1) SV2003001103A (xx)
TN (1) TNSN03139A1 (xx)
UY (1) UY27344A1 (xx)
WO (1) WO2003000295A2 (xx)
ZA (1) ZA200308561B (xx)

Families Citing this family (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040219A1 (en) * 1998-12-30 2000-07-13 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
US7732404B2 (en) * 1999-12-30 2010-06-08 Dexcel Ltd Pro-nanodispersion for the delivery of cyclosporin
JP4031232B2 (ja) * 2001-11-09 2008-01-09 カプスゲル・ジャパン株式会社 新規カプセル
MXPA04007438A (es) 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
WO2003074833A2 (en) * 2002-03-01 2003-09-12 Cesi Chemical, A Flotek Company Composition and process for well cleaning
US20040175341A1 (en) * 2003-03-04 2004-09-09 Manning Monna Marie Microemulsion for cosmetic or pharmaceutical use containing an active ingredient
KR100857759B1 (ko) * 2003-03-17 2008-09-09 니뽄 다바코 산교 가부시키가이샤 Cetp 억제제의 약제학적 조성물
CN1777419B (zh) * 2003-03-17 2010-04-28 日本烟草产业株式会社 Cetp抑制剂的药物组合物
KR20050110017A (ko) * 2003-03-17 2005-11-22 니뽄 다바코 산교 가부시키가이샤 S-'2-(''1-(2-에틸부틸)시클로헥실!카르보닐!아미노)페닐!-2-메틸프로판티오에이트의 경구 생체이용율을증가시키는 방법
TWI393560B (zh) * 2003-05-02 2013-04-21 Japan Tobacco Inc 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合
EP1653927B1 (en) * 2003-08-04 2012-01-11 Bend Research, Inc. Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials
EP1670765A2 (en) * 2003-09-30 2006-06-21 Pfizer Products Inc. Cetp inhibitors and metabolites thereof
CN1863778A (zh) * 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
US20050220866A1 (en) * 2004-04-02 2005-10-06 Dr. Reddy's Laboratories Limited Novel capsule formulations of etoposide for oral use
WO2006069162A1 (en) 2004-12-20 2006-06-29 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds and their pharmaceutical compositions
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
CN103102303B (zh) 2004-12-31 2015-10-28 雷迪博士实验室有限公司 作为cetp抑制剂的苄胺衍生物
US20090169583A1 (en) * 2005-02-08 2009-07-02 Pfizer, Inc. Solid Adsorbates of Hydrophobic Drugs
US7623458B2 (en) * 2005-09-30 2009-11-24 The Boeing Company System and method for providing integrated services across cryptographic boundaries in a network
ATE516016T1 (de) 2005-12-05 2011-07-15 Merck Sharp & Dohme Selbstemulgierende formulierungen von cetp- hemmern
JP5844954B2 (ja) * 2005-12-31 2016-01-20 天士力製薬集団株式会社 アリタソウの抽出物を含有する医薬組成物、それらの製造方法
JP2009542677A (ja) * 2006-06-30 2009-12-03 シェーリング コーポレイション トロンビン受容体拮抗薬の固形製剤
EP1961412A1 (en) 2006-12-27 2008-08-27 LEK Pharmaceuticals D.D. Self-microemulsifying drug delivery systems
US9222013B1 (en) 2008-11-13 2015-12-29 Cesi Chemical, Inc. Water-in-oil microemulsions for oilfield applications
SG172003A1 (en) * 2008-12-08 2011-07-28 Hoffmann La Roche Combined drug administration
US20100273730A1 (en) * 2009-04-27 2010-10-28 Innopharmax, Inc. Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof
EP2442791B1 (en) 2009-06-16 2019-11-27 Pfizer Inc. Dosage forms of apixaban
EA201391742A1 (ru) * 2011-05-20 2014-04-30 Авентис Фармасьютикалз Инк. Фармацевтическая композиция, включающая фексофенадин
KR101774223B1 (ko) 2011-08-18 2017-09-12 닥터 레디스 레보러터리즈 리미티드 콜레스테릴 에스테르-전달 단백질(cetp) 억제제인 치환된 헤테로시클릭 아민 화합물
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質(cetp)インヒビターとしての5−ベンジルアミノメチル−6−アミノピラゾロ[3,4−b]ピリジン誘導体
EP2768486B1 (en) * 2011-10-21 2018-10-03 First Tech International Limited Tocotrienol compositions
US20130292121A1 (en) 2012-04-15 2013-11-07 Cesi Chemical, Inc. Surfactant formulations for foam flooding
US9200192B2 (en) 2012-05-08 2015-12-01 Cesi Chemical, Inc. Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
US11407930B2 (en) 2012-05-08 2022-08-09 Flotek Chemistry, Llc Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US10053619B2 (en) 2013-03-14 2018-08-21 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US11254856B2 (en) 2013-03-14 2022-02-22 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9868893B2 (en) 2013-03-14 2018-01-16 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9464223B2 (en) 2013-03-14 2016-10-11 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9428683B2 (en) 2013-03-14 2016-08-30 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10577531B2 (en) 2013-03-14 2020-03-03 Flotek Chemistry, Llc Polymers and emulsions for use in oil and/or gas wells
US10421707B2 (en) 2013-03-14 2019-09-24 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US10717919B2 (en) 2013-03-14 2020-07-21 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US9884988B2 (en) 2013-03-14 2018-02-06 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10287483B2 (en) 2013-03-14 2019-05-14 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol
US10000693B2 (en) 2013-03-14 2018-06-19 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
US10941106B2 (en) 2013-03-14 2021-03-09 Flotek Chemistry, Llc Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells
US11180690B2 (en) 2013-03-14 2021-11-23 Flotek Chemistry, Llc Diluted microemulsions with low surface tensions
US9068108B2 (en) 2013-03-14 2015-06-30 Cesi Chemical, Inc. Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
US10590332B2 (en) 2013-03-14 2020-03-17 Flotek Chemistry, Llc Siloxane surfactant additives for oil and gas applications
US9321955B2 (en) 2013-06-14 2016-04-26 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
CN104706587A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种依托咪酯脂肪乳浓缩液、其制备方法及用途
CN104706586A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途
CN104706689A (zh) * 2013-12-16 2015-06-17 天津迈迪瑞康生物医药科技有限公司 一种鸦胆子油脂肪乳浓缩液、其制备方法及用途
US9890624B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with a polymeric material
US9890625B2 (en) 2014-02-28 2018-02-13 Eclipse Ior Services, Llc Systems and methods for the treatment of oil and/or gas wells with an obstruction material
US9505970B2 (en) 2014-05-14 2016-11-29 Flotek Chemistry, Llc Methods and compositions for use in oil and/or gas wells
CA2898770C (en) 2014-07-28 2019-05-21 Cesi Chemical, Inc. Methods and compositions related to gelled layers in oil and/or gas wells
RU2746548C2 (ru) 2014-11-04 2021-04-15 Иннофармакс, Инк. Пероральное введение неустойчивых или плохо всасывающихся лекарственных средств
CN104546710A (zh) * 2014-12-20 2015-04-29 长沙佰顺生物科技有限公司 一种安塞曲匹纳米乳及其制备方法
CN104490775A (zh) * 2014-12-20 2015-04-08 长沙佰顺生物科技有限公司 一种安塞曲匹脂肪乳及其制备方法
KR101590072B1 (ko) * 2014-12-23 2016-01-29 한미약품 주식회사 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
EP3302429A1 (en) 2015-05-28 2018-04-11 Dr. Reddy's Laboratories Ltd. Oral composition of celecoxib for treatment of pain
AU2017248828A1 (en) 2016-04-15 2018-11-01 Janssen Sciences Ireland Uc Combinations and methods comprising a capsid assembly inhibitor
US10934472B2 (en) 2017-08-18 2021-03-02 Flotek Chemistry, Llc Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods
WO2019108971A1 (en) 2017-12-01 2019-06-06 Flotek Chemistry, Llc Methods and compositions for stimulating the production of hydrocarbons from subterranean formations
CN111867582A (zh) 2018-03-14 2020-10-30 爱尔兰詹森科学公司 衣壳组装调节剂给药方案
SI3886813T1 (sl) 2018-11-26 2023-05-31 Hepion Pharmaceuticals, Inc. Farmacevtske formulacije analogov ciklosporina
CA3134550A1 (en) * 2019-04-11 2020-10-15 R.P. Scherer Technologies, Llc Formulation for oral delivery of proteins, peptides and small molecules with poor permeability
CN110252395B (zh) * 2019-07-01 2020-10-16 湖北远大生命科学与技术有限责任公司 一种用于制备高纯度牛磺酸的催化剂及其应用
US11104843B2 (en) 2019-10-10 2021-08-31 Flotek Chemistry, Llc Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency
FR3110852B1 (fr) 2020-05-27 2024-03-15 Centre Nat Rech Scient Emulsions pour liberation controlee de medicaments
US11512243B2 (en) 2020-10-23 2022-11-29 Flotek Chemistry, Llc Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI65914C (fi) * 1978-03-07 1984-08-10 Sandoz Ag Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a
GB9208712D0 (en) 1992-04-22 1992-06-10 Sandoz Ltd Pharmaceutical compositions containing cyclosporin derivates
AU2517095A (en) 1994-05-19 1995-12-18 R.P. Scherer International Corporation Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions
WO1996033697A1 (fr) * 1995-04-24 1996-10-31 Yissum Research Development Company Of The Hebrew University Of Jerusalem Formulation auto-emulsionnable formant une emulsion huile dans l'eau
GB9608719D0 (en) 1996-04-26 1996-07-03 Scherer Ltd R P Pharmaceutical compositions
US5993858A (en) * 1996-06-14 1999-11-30 Port Systems L.L.C. Method and formulation for increasing the bioavailability of poorly water-soluble drugs
CZ291641B6 (cs) 1996-06-19 2003-04-16 Novartis Ag Přípravek obsahující cyklosporin
US5958876A (en) * 1996-06-19 1999-09-28 Novartis Ag Cyclosporin-containing pharmaceutical compositions
JP2894445B2 (ja) * 1997-02-12 1999-05-24 日本たばこ産業株式会社 Cetp活性阻害剤として有効な化合物
WO1999014204A1 (en) * 1997-09-16 1999-03-25 G.D. Searle & Co. Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity
DE19741399A1 (de) * 1997-09-19 1999-03-25 Bayer Ag Tetrahydrochinoline
US6063762A (en) 1997-12-05 2000-05-16 Chong Kun Dang Corp. Cyclosporin-containing microemulsion preconcentrate composition
WO1999041237A1 (en) * 1998-02-13 1999-08-19 G.D. Searle & Co. Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity
US6147090A (en) * 1998-09-17 2000-11-14 Pfizer Inc. 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
GT199900147A (es) * 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6140342A (en) * 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
US6147089A (en) * 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
CA2345108A1 (en) * 1998-09-25 2000-04-06 Monsanto Company Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity
WO2000040219A1 (en) 1998-12-30 2000-07-13 Dexcel Ltd. Dispersible concentrate for the delivery of cyclosporin
CO5271716A1 (es) * 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
US6482862B1 (en) * 1999-12-20 2002-11-19 G.D. Searle & Co. Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity
US7115279B2 (en) * 2000-08-03 2006-10-03 Curatolo William J Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
EP1269994A3 (en) * 2001-06-22 2003-02-12 Pfizer Products Inc. Pharmaceutical compositions comprising drug and concentration-enhancing polymers
ATE361758T1 (de) * 2001-06-22 2007-06-15 Pfizer Prod Inc Pharmazeutische zusammensetzungen enthaltend eine feste dispersion eines im wasser schwerlöslichen arzneimittels und ein löslichkeitsteigerndes polymer
WO2003000226A2 (en) * 2001-06-22 2003-01-03 Pfizer Products Inc. Pharmaceutical compositions containing polymer and drug assemblies
PT1404300E (pt) * 2001-06-22 2009-11-09 Bend Res Inc Composições farmacêuticas de dispersões de fármacos e polímeros neutros
MXPA04007438A (es) * 2002-02-01 2004-10-11 Pfizer Prod Inc Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas.
EP1469829B1 (en) * 2002-02-01 2016-01-27 Bend Research, Inc Immediate release dosage forms containing solid drug dispersions
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
ATE389396T1 (de) * 2002-12-20 2008-04-15 Pfizer Prod Inc Dosierungsform enthaltend einen cetp-hemmer und einen hmg-coa reduktase hemmer

Also Published As

Publication number Publication date
PL368850A1 (en) 2005-04-04
ECSP034875A (es) 2004-01-28
NO20035632L (no) 2004-02-18
PA8548601A1 (es) 2003-09-05
EP1453544A2 (en) 2004-09-08
EA200301139A1 (ru) 2004-12-30
IS7014A (is) 2003-10-31
MA27034A1 (fr) 2004-12-20
CZ20033341A3 (cs) 2004-10-13
GT200200124A (es) 2003-09-22
US6962931B2 (en) 2005-11-08
OA12619A (en) 2006-06-12
CA2455288A1 (en) 2003-01-03
MXPA04000014A (es) 2004-05-21
IL158765A0 (en) 2004-05-12
CR7163A (es) 2004-02-23
KR20040015746A (ko) 2004-02-19
BG108486A (bg) 2005-03-31
US20060014788A1 (en) 2006-01-19
HN2002000153A (es) 2002-11-05
EE200400024A (et) 2004-06-15
AP2002002559A0 (en) 2002-06-30
NO20035632D0 (no) 2003-12-17
SK15172003A3 (en) 2004-11-03
HUP0400263A2 (hu) 2005-03-29
CN1635911A (zh) 2005-07-06
BR0210505A (pt) 2004-05-18
SV2003001103A (es) 2003-03-18
JP2005500314A (ja) 2005-01-06
TNSN03139A1 (fr) 2005-12-23
WO2003000295A2 (en) 2003-01-03
WO2003000295A3 (en) 2004-05-27
UY27344A1 (es) 2003-01-31
AR034599A1 (es) 2004-03-03
US20030022944A1 (en) 2003-01-30
PE20030128A1 (es) 2003-02-28

Similar Documents

Publication Publication Date Title
ZA200308561B (en) Self-emulsifying formulations of cholesteryl ester transfer protein inhibitors.
AU2914202A (en) Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors
AUPR392301A0 (en) Protein phosphatase inhibitors
AU2002213485A1 (en) Inhibitors of protein kinases
AU2001293564A1 (en) Point of sale terminal
GB0322515D0 (en) Enzymes for specific fragmentation of proteins
DK1216025T3 (da) Dispersionsformuleringer indeholdende lipaseinhibitorer
MXPA03000694A (es) Nuevo uso de los inhibidores de lipasa.
AU2002355551A1 (en) Antisense modulation of cholesteryl ester transfer protein expression
AU2001293538A1 (en) Novel protein tyrosine phosphatase inhibitor
AUPQ596600A0 (en) Point of sale system
AU2002342417A1 (en) Inhibitors of dna methyltransferase isoforms
AU2002305868A1 (en) Inhibitors of reggamma
AU1212002A (en) Use of lipase inhibitors
AU2002221882A1 (en) Use of 3-hydroxyl-3-methylglutaryl-coenzyme-a-reductase inhibitors
AU2002325827A1 (en) Compositions and methods for detecting or regulating cholesteryl ester transfer protein
AU2001297794A1 (en) Methods and compositions of human proteins and uses thereof.
AU2003237157A1 (en) Preparation of phosphatase inhibitors
EP1238585B8 (de) Verwendung von Esterquats
AU2002222472A1 (en) Backbone cyclized inhibitors of heat shock proteins
AU2002253372A1 (en) Composition comprising phosphodiesterase inhibitors for inducing cervical ripening
AU2002343277A1 (en) Point of sale system
AUPR867601A0 (en) Point of sale system
GB0125867D0 (en) Isolation of protein
AU2002337107A1 (en) 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors